U.S. medical device company Nuvaira has completed a $79 million equity financing.
Nuvaira intends to use the funds to support the pivotal AIRFLOW-3 clinical trial for Food and Drug Administration approval and to implement a targeted clinical growth strategy in key European markets.
The round was led by U.S. Venture Partners joined by Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation as well as all of the company's existing backers.
Nuvaira, which generates about $7 million in revenue annually, has bagged a total of $68.6 million in over five funding rounds.